AMAG Pharmaceuticals Inc

Find Ratings Reports
AMAG : NASDAQ : Health Care
$26.35 up 0.05 | 0.19%
Today's Range: 25.25 - 26.60
Avg. Daily Volume: 755,800
10/25/16 - 4:14 PM ET

Financial Analysis

AMAG PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. AMAG PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.06 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 28.49% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)127.42123.88
EBITDA ($mil)54.486.76
EBIT ($mil)32.8266.9
Net Income ($mil)-0.633.26

Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)546.47398.41
Total Assets ($mil)2480.811639.28
Total Debt ($mil)989.11483.2
Equity ($mil)916.17712.98

Profitability Q2 FY16 Q2 FY15
Gross Profit Margin89.2270.03
EBITDA Margin42.6970.03
Operating Margin25.7654.0
Sales Turnover0.180.18
Return on Assets-0.8611.62
Return on Equity-2.3426.73
Debt Q2 FY16 Q2 FY15
Current Ratio2.241.71
Interest Expense18.2510.21
Interest Coverage1.86.56

Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)34.1530.87
Div / share0.00.0
Book value / share26.8223.1
Institutional Own % n/a n/a
Avg Daily Volume758314.01056675.0


HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 0.94 indicates a significant discount versus the S&P 500 average of 2.73 and a significant discount versus the industry average of 9.83. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the industry average, indicating a discount. After reviewing these and other key valuation criteria, AMAG PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AMAG NM Peers 41.80   AMAG 6.87 Peers 20.57

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

AMAG's P/E is negative making this valuation measure meaningless.


Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AMAG is trading at a significant discount to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
AMAG 3.96 Peers 33.61   AMAG NA Peers 0.46

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

AMAG is trading at a significant discount to its peers.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AMAG 0.94 Peers 9.83   AMAG -111.11 Peers 0.11

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AMAG is trading at a significant discount to its peers.


Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, AMAG is expected to significantly trail its peers on the basis of its earnings growth rate.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AMAG 1.96 Peers 563.14   AMAG 51.16 Peers 50.92

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AMAG is trading at a significant discount to its industry on this measurement.


Average. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.

AMAG is keeping pace with its peers on the basis of sales growth.



Latest Stock Upgrades/Downgrades